XOPENEX HFA(R) Data to Be Presented at American College of Allergy, Asthma and Immunology Annual Meeting
Sepracor Inc. (Nasdaq: SEPR) today announced that clinical data for XOPENEX HFA® (levalbuterol tartrate) Inhalation Aerosol will be presented at the American College of Allergy, Asthma and Immunology annual meeting in Philadelphia on November 11 and 12, 2006.
The poster entitled, “Cumulative Dose Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Patients with Asthma” will be displayed in Exhibit Hall D of the Pennsylvania Convention Center. The investigator will be available to discuss the poster from 12:00 to 1:00 p.m. ET on both days.
About XOPENEX HFA Inhalation Aerosol
XOPENEX HFA is a hydrofluoroalkane (HFA) metered-dose inhaler (MDI), which is a portable, hand-held device consisting of a pressurized canister containing medication and a mouthpiece through which the medication is inhaled. XOPENEX HFA is indicated for the treatment or prevention of bronchospasm in adults, adolescents and children 4 years of age and older with reversible obstructive airway disease.
About Asthma
Asthma is a chronic lung disorder characterized by reversible airway obstruction and the pathologic finding of airway inflammation. According to the 2002 National Health Interview Survey conducted by the Centers for Disease Control and Prevention, nearly 31 million Americans have been diagnosed with asthma in their lifetime. It is the most common childhood illness and affects nearly 9 million children in the U.S. under the age of 18. Short-acting bronchodilators are the most-prescribed asthma therapy among primary care physicians and pediatricians in the U.S., according to IMS Health information.
Important Safety Information
XOPENEX HFA is contraindicated in patients with a history of hypersensitivity to levalbuterol, racemic albuterol or any other component of XOPENEX HFA. XOPENEX HFA and other beta-agonists can produce paradoxical bronchospasm, which may be life threatening. If additional adrenergic drugs, including other short-acting sympathomimetic bronchodilators or epinephrine, are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects. Due to the cardiovascular side effects associated with beta-agonists, caution is generally recommended for patients with cardiovascular disorders (especially coronary insufficiency, cardiac arrhythmias and hypertension), diabetes, hyperthyroidism, or convulsive disorders. Also, see the complete prescribing information regarding potential drug interactions with beta-blockers, diuretics, digoxin or MAOI and tricyclic antidepressants.
About Sepracor
Sepracor Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products that are directed toward serving unmet medical needs. Sepracor’s drug development program has yielded a portfolio of pharmaceutical products and candidates with a focus on respiratory and central nervous system disorders. Sepracor’s corporate headquarters are located in Marlborough, Massachusetts.
Forward-Looking Statement
This news release contains forward-looking statements that involve risks and uncertainties, including statements with respect to the safety, efficacy and potential benefits of XOPENEX HFA Inhalation Aerosol. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: Sepracor’s ability to fund, and the results of, further clinical trials; the scope of Sepracor’s patents and the patents of others; the commercial success of XOPENEX HFA; any changes in the use and/or label of XOPENEX HFA; the ability of the company to attract and retain qualified personnel; and certain other factors that are detailed in the company’s quarterly report on Form 10-Q for the quarter ended June 30, 2006 filed with the Securities and Exchange Commission.
In addition, the statements in this press release represent Sepracor’s expectations and beliefs as of the date of this press release. Sepracor anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while Sepracor may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Sepracor’s expectations or beliefs as of any date subsequent to the date of this press release.
XOPENEX HFA is a registered trademark of Sepracor Inc.
For a copy of this release or any recent release, visit Sepracor’s web site at www.sepracor.com.